$ARGX: The Biotech Face-Melter

$ARGX just nuked the bears. A 16.39% rip to $990.51 isn't just price action; it's a liquidation event. The shorts are trapped, and the street is scrambling to reprice this monster. We are sitting at a fresh 52-week high, and the volume is screaming institutional conviction—up 82.6% over the 30-day average.

The Data Breakdown

Metric	Value
Price	$990.51
1-Day Change	+16.35%
RSI	70.1 (Overbought)
Volatility	4.54%
Support	$826.45
Resistance	$1002.16

The Catalyst: Phase III Victory

The news: Argenx crushed the Phase III study for autoimmune myositis.

The So What?: The market was pricing in execution risk. This trial win de-risks the pipeline expansion for Vyvgart. When you remove that overhang, the valuation floor moves up vertically. We aren't just looking at a drug; we're looking at a franchise expansion that makes $VRTX look stagnant. Market participants were leaning bearish for seven days, creating a massive short interest pile that just hit the woodchipper. This is a classic short squeeze fueled by fundamental validation.

The Play

Resistance is at $1002.16. That’s the psychological barrier. If we crack that, we enter blue-sky territory where the shorts will cover until they’re bankrupt. Ignore the RSI reading of 70.1; in a breakout this violent, momentum indicators are just fuel. The retail crowd is panicking because they hate chasing, but this is exactly where you buy the breakout or you get left behind. If this holds, we test $1050 by EOW.

Don't look at $AMGN or $BIIB right now. They are side-shows. All the liquidity is flowing into $ARGX. If you aren't long, you're irrelevant. Watch the dark pool prints tomorrow morning. If the institutions are taking profit, you see the massive blocks print below the tape. If they are reloading, we grind higher.

Data Source: Thescanner (https://www.thescanner.ai)

---

Disclaimer: Eachi Alpha provides independent financial analysis based on algorithmic market data. This content is for informational and educational purposes only and does not constitute financial, investment, or trading advice. Trading securities involves significant risk. Eachi Alpha is not responsible for any financial losses or damages resulting from the use of this information. Always perform your own due diligence before making investment decisions.